193 related articles for article (PubMed ID: 9626802)
1. CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
Sandler A; Blanke C; Monaco F; Carey MA; Ansari R; Fisher B; Spiridonidis CH; Einhorn L; Nichols C
Am J Clin Oncol; 1998 Jun; 21(3):294-7. PubMed ID: 9626802
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study.
Yanagawa H; Bando H; Takishita Y
Anticancer Res; 1995; 15(2):613-6. PubMed ID: 7539241
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
5. Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer.
Sato K; Tsuchiya S; Minato K; Sunaga N; Ishihara SI; Makimoto T; Naruse I; Hoshino H; Watanabe S; Saitoh R; Mori M
Oncol Rep; 2000; 7(5):1135-9. PubMed ID: 10948352
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
[TBL] [Abstract][Full Text] [Related]
8. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
9. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.
Kubota K; Nishiwaki Y; Kakinuma R; Hojo F; Matsumoto T; Ohmatsu H; Sekine I; Yokozaki M; Goto K; Ebi N; Kodama T
J Clin Oncol; 1997 Jan; 15(1):292-6. PubMed ID: 8996155
[TBL] [Abstract][Full Text] [Related]
10. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
11. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
12. r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
Gautier V; Pujol JL; Zinaï A; Michel FB
Lung Cancer; 1996 Jun; 14(2-3):343-51. PubMed ID: 8794415
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.
Negoro S; Masuda N; Furuse K; Saijo N; Fukuoka M
Cancer Chemother Pharmacol; 1997; 40 Suppl():S70-3. PubMed ID: 9272138
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
Hastürk S; Kurt B; Kocabas A; Orüç O; Burgut R
J Chemother; 1997 Feb; 9(1):66-71. PubMed ID: 9106021
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
[TBL] [Abstract][Full Text] [Related]
20. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]